Abstract
The in vitro antibacterial activity of DU-6681a, a parent compound of DZ-2640, against gram-positive and -negative bacteria was compared with those of penems and cephalosporins currently available. MICs at which 90% of the isolates are inhibited (MIC90s) of the compound for clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-susceptible and -resistant strains, were 0.10, 25, and 12.5 microg/ml, respectively. DU-6681a inhibited the growth of all strains of Streptococcus pyogenes and of penicillin-susceptible and -insusceptible Streptococcus pneumoniae at 0.006, 0.025, and 0.20 microg/ml, respectively, and MIC90s of the compound were 6.25 and >100 microg/ml for Enterococcus faecalis and Enterococcus faecium, respectively. MIC90s of DU-6681a were 0.20, 0.10, and 0.025 microg/ml for Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae, respectively. For Pseudomonas aeruginosa, the MIC50 and MIC90 of DU-6681a were 25 and 50 microg/ml, respectively. DU-6681a activity was not affected by different media, varied inoculum size (10(4) to 10(7) CFU), or the addition of human serum but was decreased under acidic conditions against gram-negative bacteria, under alkaline conditions against gram-positive bacteria, and in human urine, as was the activity of the other antibiotics tested. The frequency of spontaneous resistance to DU-6681a was less than or equal to those of the reference compounds. Time-kill curve studies demonstrated the bactericidal action of DU-6681a against S. aureus, S. pneumoniae, Escherichia coli, and H. influenzae.
Full Text
The Full Text of this article is available as a PDF (255.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bush K., Jacoby G. A., Medeiros A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995 Jun;39(6):1211–1233. doi: 10.1128/aac.39.6.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cormican M. G., Jones R. N. Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria. J Antimicrob Chemother. 1995 Apr;35(4):535–539. doi: 10.1093/jac/35.4.535. [DOI] [PubMed] [Google Scholar]
- Inoue E., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic. Antimicrob Agents Chemother. 1994 Sep;38(9):1974–1979. doi: 10.1128/aac.38.9.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knapp C. C., Sierra-Madero J., Washington J. A. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agents Chemother. 1988 Dec;32(12):1896–1898. doi: 10.1128/aac.32.12.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Minami S., Yotsuji A., Inoue M., Mitsuhashi S. Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother. 1980 Sep;18(3):382–385. doi: 10.1128/aac.18.3.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakagawa S., Hashizume T., Matsuda K., Sanada M., Okamoto O., Fukatsu H., Tanaka N. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity. Antimicrob Agents Chemother. 1993 Dec;37(12):2756–2759. doi: 10.1128/aac.37.12.2756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Saha G., Chin N. X. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother. 1989 Oct;33(10):1795–1800. doi: 10.1128/aac.33.10.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ohba F., Nakamura-Kamijo M., Watanabe N., Katsu K. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298–307. doi: 10.1128/aac.41.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saino Y., Kobayashi F., Inoue M., Mitsuhashi S. Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother. 1982 Oct;22(4):564–570. doi: 10.1128/aac.22.4.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spangler S. K., Jacobs M. R., Appelbaum P. C. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother. 1994 Dec;38(12):2902–2904. doi: 10.1128/aac.38.12.2902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waley S. G. A spectrophotometric assay of beta-lactamase action on penicillins. Biochem J. 1974 Jun;139(3):789–790. doi: 10.1042/bj1390789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Ashby J. P., Thornber D. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins. J Antimicrob Chemother. 1990 Apr;25(4):541–550. doi: 10.1093/jac/25.4.541. [DOI] [PubMed] [Google Scholar]